US-based therapeutic products developer Tris Pharma has acquired Pfizer’s wholly-owned subsidiary NextWave Pharmaceuticals, for an undisclosed amount.
The deal expands Tris Pharma’s portfolio focused on the treatment of attention deficit hyperactivity disorder (ADHD) by adding two therapies created by NextWave, Quillivant XR and QuilliChew ER.
Go deeper with GlobalData
Quillivant XR is an oral liquid methylphenidate, while QuilliChew ER is a methylphenidate chewable tablet. Both are extended-release formulations and central nervous system (CNS) stimulants indicated for ADHD.
Tris Pharma co-developed these ADHD treatments with NextWave using its LiquiXR platform. Tris continued to manufacture the products even after Pfizer acquired NextWave in 2012.
The company’s president and CEO Ketan Mehta said: “As co-developer of Quillivant XR and QuilliChew ER, we are excited to bring commercialisation of these products in house and expand our ADHD portfolio.
“To further support our newest acquisition, Tris is expanding our commercial footprint and building a world class medical affairs group.”
Tris’ portfolio for ADHD comprises a liquid amphetamine called DYANAVEL XR. The product was launched in 2016 for the treatment of the disorder in children aged six years and above.
Tris Pharma chief medical officer Barry Herman said: “Our newest acquisition brings us one step closer to realising our corporate mission, to develop and expand offerings to meet unmet needs for all patients.
“With three treatment options for patients with ADHD, Tris now offers a broad, established product portfolio with both stimulant classes in the ADHD space.”
In addition to DYANAVEL XR, the company provides a variety of generics such as Dexmethylphenidate, Methylphenidate, Dextroamphetamine, Theophylline Oral and Morphine Sulfate in the US.
